The development of breast cancer control strategies in women at high genetic risk of breast
cancer is an important issue. The likely benefit of chemopreventive approaches is of …

The management of breast cancer prone women remains a tough issue despite the release
of institutional guidelines. Currently, only the anti-estrogen agent Tamoxifen and …

We have analysed the pedigrees of all 70 women who developed cancer in the Royal
Marsden Hospital (RMH) tamoxifen chemoprevention trial, using the Claus model, to assess …

Purpose Chemoprevention with a selective estrogen receptor modulator (tamoxifen or
raloxifene) is a non-surgical option offered to high-risk women to reduce the risk of breast …

The purpose of our study was to review the evidence for the efficacy of surveillance for early
detection, bilateral prophylactic mastectomy, prophylactic oophorectomy and …

Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of
approximately 80%. Tamoxifen treatment of the first cancer has been associated with a …

TO THE EDITOR: Tamoxifen, or another type of adjuvant hormonal therapy, is often
prescribed to women who are diagnosed with estrogen receptor–positive breast cancer, with …

ContextAmong cancer-free women aged 35 years or older, tamoxifen reduced the incidence
of estrogen receptor (ER)–positive but not ER-negative breast cancer. The effect of …

Purpose: To assess physician recommendations about the use of tamoxifen in
premenopausal BRCA1 and BRCA2 mutation carriers. Methods: We mailed surveys to a …

Purpose To determine whether adjuvant tamoxifen treatment for breast cancer (BC) is
associated with reduced contralateral breast cancer (CBC) risk for BRCA1 and/or BRCA2 …